These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 38510674)

  • 21. Current intravitreal pharmacologic therapies for diabetic macular edema.
    Colucciello M
    Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of Intravitreal Injection of Anti-vascular Endothelial Growth Factor Drugs on Ocular Blood Vessels and Blood Flow in Patients with Diabetic Retinopathy].
    Huang H; Shi L; Li S; Wu N; Rao J; Wu YJ; Wu XR
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):796-800. PubMed ID: 34728042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging the Retinal Vascular Mural Cells In Vivo: Elucidating the Timeline of Their Loss in Diabetic Retinopathy.
    Huang BB; Fukuyama H; Burns SA; Fawzi AA
    Arterioscler Thromb Vasc Biol; 2024 Feb; 44(2):465-476. PubMed ID: 38152885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cell biology of intraocular vascular diseases].
    Ishibashi T
    Nippon Ganka Gakkai Zasshi; 1999 Dec; 103(12):923-47. PubMed ID: 10643294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the treatment of diabetic retinopathy.
    Singh RP; Elman MJ; Singh SK; Fung AE; Stoilov I
    J Diabetes Complications; 2019 Dec; 33(12):107417. PubMed ID: 31669065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy.
    Arrigo A; Aragona E; Bandello F
    Ann Med; 2022 Dec; 54(1):1089-1111. PubMed ID: 35451900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Modern approach to early diagnosis and pathogenetic treatment of diabetic retinopathy].
    Vorob'eva IV
    Vestn Oftalmol; 2016; 132(5):60-67. PubMed ID: 27911427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of an immersive, interactive medical education initiative on guideline-based retinal disease management knowledge/competence and effectual practice change.
    Singh RP; Welch L; Longo NL; Frese M
    BMC Ophthalmol; 2023 Jun; 23(1):285. PubMed ID: 37349689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subthreshold Compared with Threshold Macular Photocoagulation for Diabetic Macular Edema: A Systematic Review and Meta-Analysis.
    Tai F; Nanji K; Garg A; Zeraatkar D; Phillips M; Steel DH; Garg SJ; Kaiser PK; Guymer RH; Wykoff CC; Sivaprasad S; Chaudhary V
    Ophthalmol Retina; 2024 Mar; 8(3):223-233. PubMed ID: 37805099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept.
    Blindbæk SL; Peto T; Grauslund J
    Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Laser Therapy in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema.
    Everett LA; Paulus YM
    Curr Diab Rep; 2021 Sep; 21(9):35. PubMed ID: 34487257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial.
    Li S; Tao Y; Yang M; Zhao H; Si M; Cui W; Wang H
    Front Endocrinol (Lausanne); 2024; 15():1286736. PubMed ID: 38455651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.
    Stewart MW
    Ophthalmol Ther; 2017 Jun; 6(1):33-47. PubMed ID: 28324452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetic Retinopathy: An Overview of Treatments.
    Mounirou BAM; Adam ND; Yakoura AKH; Aminou MSM; Liu YT; Tan LY
    Indian J Endocrinol Metab; 2022; 26(2):111-118. PubMed ID: 35873941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-VEGF Therapy for Diabetic Eye Diseases.
    Bahrami B; Hong T; Gilles MC; Chang A
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):535-545. PubMed ID: 29076303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy.
    Tomita Y; Lee D; Tsubota K; Negishi K; Kurihara T
    J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
    Uludag G; Hassan M; Matsumiya W; Pham BH; Chea S; Trong Tuong Than N; Doan HL; Akhavanrezayat A; Halim MS; Do DV; Nguyen QD
    Expert Opin Biol Ther; 2022 Oct; 22(10):1275-1291. PubMed ID: 35818801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab for diabetic retinopathy.
    Arevalo JF; Garcia-Amaris RA
    Curr Diabetes Rev; 2009 Feb; 5(1):39-46. PubMed ID: 19199897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetic retinopathy and angiogenesis.
    Crawford TN; Alfaro DV; Kerrison JB; Jablon EP
    Curr Diabetes Rev; 2009 Feb; 5(1):8-13. PubMed ID: 19199892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Aging and retinal vascular diseases].
    Takagi H
    Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):207-30; discussion 231. PubMed ID: 17402563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.